Neuren Pharmaceuticals Ltd has released a press release.
Rett Syndrome NDA accepted for Priority Review by FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- S&P DJI Announces September 2022 Quarterly Rebalance
- Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
- Quarterly Activities/Appendix 4C Cash Flow Report
- Acadia submits Rett Syndrome New Drug Application to the FDA
- Neuren commences Phase 2 trial of NNZ-2591 in Angelman
Later from Neuren Pharmaceuticals
- Neuren receives US$10 million milestone payment
- Q3 2022 quarterly activity and cash flow report
- Neuren submits IND & first patients complete Phase 2 trials
- Prader-Willi syndrome IND for NNZ-2591 approved by FDA
- Q4 2022 quarterly activity and cash flow report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals